The MTHFD enzyme family is central to one-carbon metabolism, with MTHFD2 showing cancer-selective overexpression linked to poor prognosis. Emerging data also identify MTHFD1 as a therapeutic vulnerability in select tumors, supporting MTHFD-targeted drug development.